Article Per Year (5 Year)
p-Index From 2021 - 2026
1.116
P-Index
This Author published in this journals
All Journal Journal of Epidemiology and Public Health Oto Rhino Laryngologica Indonesiana Sumatera Medical Journal International Journal of Nasopharyngeal Carcinoma Narra J
Delfitri Munir
Faculty Of Medicine Universitas Sumatera Utara
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 13 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Narra J

 1 
Mesenchymal stem cells for immune modulation in systemic lupus erythematosus: From bench research to clinical applications Ginting, Andi R.; Munir, Delfitri; Amin, Mustafa M.; Darlan, Dewi M.; Putra, Agung; Rusda, Muhammad; Mutiara, Erna; Mayasari, Evita; Rozi, Muhammad F.
Narra J Vol. 4 No. 3 (2024): December 2024
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v4i3.994

Abstract

Systemic lupus erythematosus (SLE) is a prevalent autoimmune disease affecting multiple organ systems. Disease progression is inevitable as part of its natural course, necessitating aggressive therapeutic strategies, particularly with the use of immunosuppressants. Long-term use of steroids and other immunosuppressants is associated with significant adverse effects. Mesenchymal stem cells (MSCs) have been shown to modulate the immune response, leading to immunosuppressive effects against self-antigens. MSCs have demonstrated the ability to modulate several immune cell populations, contributing to favorable outcomes in controlling immune and inflammatory conditions. Recent evidence has shown an increase in Treg and Breg cell subsets following MSC administration, along with modulation of other immune cells, including dendritic cells, B cells, and T cells. However, the balance between MSC pro-inflammatory and anti-inflammatory phenotypic activation remains a critical factor in determining therapeutic outcomes. Various covariates also influence the efficacy of MSC therapy. The aim of this study was to provide a comprehensive overview of the utilization of mesenchymal stem cells (MSCs) in SLE treatment, leveraging their immunomodulatory and immunosuppressive capabilities. Understanding the fundamental preclinical effects of MSCs and recent findings from clinical studies may enhance the potential of MSC therapy in the management of SLE patients.
Therapeutic potential of thymoquinone in regulating p63, claudin, and periostin in chronic rhinosinusitis with nasal polyps: An animal model study Ulfa, Loriana; Munir, Delfitri; Rambe, Andrina YM.; Farhat, Farhat; Wardani, Retno S.; Amin, Mustafa M.; Zahara, Devira; Ardinata, Dedi
Narra J Vol. 5 No. 1 (2025): April 2025
Publisher : Narra Sains Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52225/narra.v5i1.1728

Abstract

High recurrence rate and the necessity for repeated surgical interventions contribute to the chronicity and treatment-resistant nature of chronic rhinosinusitis with nasal polyps (CRSwNP). Thymoquinone, known for its protective effects on epithelial integrity, has not been previously explored in CRSwNP. The aim of this study was to investigate the therapeutic potential of thymoquinone to restore epithelial integrity by assessing p63 transcription factor and claudin protein expressions, as well as periostin mRNA expression in an animal model. An in vivo study using post-test-only control group design was conducted in which male Wistar rats were randomly assigned to three groups, each consisting of 10 animals: healthy group, CRSwNP group, and thymoquinone-treated group for three weeks. Immunohistochemistry was used to analyze the p63 and claudin protein expressions, while periostin mRNA expression was quantified using quantitative reverse transcription polymerase chain reaction (qRT-PCR). This study found that thymoquinone significantly reduced p63 transcription factor expression compared to the untreated CRSwNP group (p=0.009). Claudin protein expression was significantly higher in thymoquinone-treated group compared to CRSwNP group (p=0.007), indicating improved epithelial barrier function. Periostin mRNA expression showed no significant difference between healthy and thymoquinone-treated groups (p=0.564), but a significant decrease was observed in CRSwNP group compared to thymoquinone-treated group (p=0.000) and between the healthy and CRSwNP groups (p=0.002), suggesting attenuation of tissue remodeling and inflammation. In conclusion, thymoquinone could enhance sinonasal epithelial barrier integrity in CRSwNP by downregulating p63 transcription factor, upregulating claudin protein expression, and reducing periostin mRNA expression. These findings emphasize the potential of thymoquinone as a therapeutic agent to mitigate inflammation and tissue remodeling in CRSwNP, warranting further investigation as a novel treatment option.
Co-Authors -, Fadhlia Adlin Adnan Agung Putra Amin, Mustafa M. Andrina Yunita Murni Rambe Ardinata, Dedi - Arlinda Sari Wahyuni Asnir, Rizalina Arwinati Chrestella, Jessy Darlan, Dewi M. Dolly Irfandy Elisabeth Erna Mutiara Evita Mayasari Farhat, Farhat Farhat, Farhat Ginting, Andi R. Haryuna, Tengku Siti Hajar Hasibuan, Mangain Hendradewi, Sarwastuti Ibrahim Irsan Nasution Kusuma Dewi, Anna Mailasari Magdalena Simatupang, Maria Magdi, Yoan Levia Manullang, Frenky Sorimuda Nurdiansah, Firman Pardede, Sujahn Anto Putri Chairani Eyanoer, Putri Chairani Rambe, Andriana Yunita Murni Rambe, Andrina Y.M Rambe, Andrina YM. Rambe, Andrina Yunita Murni Ramsi Lutan Rasiyanti Siregar, Olga Restimulia, Lia Rina Yunita Rozi, Muhammad F. Rusda, Muhammad sagala, irwan pernandi Sagala, Irwan Pernandi Silvia, S Simanjuntak, Amran Sinta Sari Ratunanda Siska Indriany Sorimuda Sarumpaet Sutikno, Budi Taufik Ashar Ulfa, Loriana Wardani, Retno S. Wardani, Retno Sulistyo Zahara, Devira Zakiah, Azmi Mir’ah